More than 80 global executives gathered in Beijing for the China Development Forum, signaling renewed corporate interest in the Chinese market despite ongoing geopolitical tensions. The discussions reflected a cautious but clear pivot toward expansion, as Beijing continues to gradually ease restrictions on foreign businesses.Eli Lilly Expands China Bet With Obesity Drug FocusIn March, Eli Lilly outlined an aggressive long-term strategy for China, announcing plans to invest $3 billion in the country over the ...

Core Viewpoint - Eli Lilly has experienced significant stock growth, with a 400% increase over the past five years, but its high valuation raises questions about future investment potential [2]. Group 1: Stock Performance and Valuation - Eli Lilly's current market cap exceeds $800 billion, and it trades at approximately 40 times its trailing earnings [2]. - The consensus analyst price target for Eli Lilly is slightly over $1,221, indicating a potential upside of about 35% from its current price [6]. - Despite a 16% decline in stock value this year, Eli Lilly has been underperforming compared to the S&P 500 [9]. Group 2: Earnings and Growth Potential - In the fourth quarter of 2025, Eli Lilly reported a 43% increase in sales to $19.3 billion and a 50% rise in net income to $6.6 billion, driven by its popular GLP-1 drugs, Mounjaro and Zepbound [7]. - Analysts maintain a bullish outlook, with 25 out of the last 30 ratings being buy ratings, reflecting strong growth expectations [6][8]. - Long-term investors may see even stronger returns if Eli Lilly continues to lead in the GLP-1 market [8].

在阿斯利康宣布计划于2030年前在中国投资逾1000亿元人民币（150亿美元），以扩大在药品 生产与研发领域的布局后， 多家跨国药企（MNC）接连宣布加大中国市场投资。 近日，中国发展高层论坛2026年年会现场涌动着一股"MNC投资热度"。诺华公司首席执 行官万思瀚（Vasant Narasimhan）在"健康中国2030"与大健康产业发展专题研讨会上宣 布，诺华计划在华投入超过33亿元人民币启动大规模投资扩建。而在同一周，阿斯利康刚 刚宣布在上海和广州落子两大重磅生产基地，礼来则抛出了未来十年累计投资30亿美元的 计划。 记者丨季媛媛 编辑丨张明艳 跨国药企投资中国成为当下的一大热点。 在中国发展高层论坛2026年年会召开前夕，阿斯利康宣布在上海建设细胞疗法生产供应基地 与创新中心，打造端到端的细胞治疗能力；几乎同时，其在广州的放射性偶联药物生产供应 基地也浮出水面。这两大基地的协同，将显著增强阿斯利康在新型药物及疗法领域的本地化 生产能力。 阿斯利康全球执行副总裁、国际业务负责人尹思睿（Iskra Reic）表示："三十余年来，我们始 终与中国携手合作，为患者带来科学突破成果。依托今年1月宣布的逾1000 ...

2026.03. 23 本文字数：1454，阅读时长大约2分钟 刚刚过去的这一周，阿斯利康接连宣布要在华建立两个基地，一是在上海建立细胞疗法商业化生产供 应基地与创新中心；二是在广州建设放射性偶联药物生产供应基地。 作者 | 第一财经 林志吟 3月22日，诺华公司宣布将持续加大在华投资，扩大在中国研发、生产及运营布局，预计将投入金额 超过33亿元。 从诺华公司发布的消息看，这项大规模的投资计划将在今年启动。 诺华方面介绍称，诺华昌平工厂始建于1987年，具备年产30亿片（粒）制剂及5.5亿盒包装的最大产 能，是诺华全球制造供应网络中的重要生产基地。当前，工厂已启动新一轮厂区扩建升级项目，并规 划未来持续投入约15亿元，用于建设新厂房及配套设施，引入无菌制备工艺、液体灌装及包装等全 新生产技术和设备。 此外，诺华中国总部所在地——上海园区将在今年迎来投入运营十周年的里程碑。诺华已计划联合投 资人共同出资18亿元人民币，启动上海园区二期项目建设。 今年以来，密集有跨国药企宣布在华启动大规模投资计划。 同样在3月份，礼来宣布，计划未来十年累计投资30亿美元全面扩展在华供应链产能，打造口服固体 制剂本土生产与供应体系 ...

Core Insights - Eli Lilly and Company is recognized as a strong investment opportunity, particularly with the launch of its weight-loss drug Zepbound, which will be available for self-pay at $299 per month for the 2.5 mg dose [1] Group 1: Product Launch and Pricing - Zepbound, a once-weekly injectable for adults with obesity or overweight-related conditions, will be available for self-pay starting at $299 per month [1][2] - A new savings card will allow eligible adults with a valid prescription to access the same pricing nationwide, although it is limited to the KwikPen format [2] Group 2: Access and Cost Reduction Initiatives - Eli Lilly received a boost from new Medicare and Medicaid services implementation details aimed at enhancing access to medications at lower costs [3] - With the new Medicare and Medicaid Services details, Zepbound and other medications will be available through Medicare Part D plans, capping out-of-pocket costs for beneficiaries at $50 a month, with cost-sharing limited to $245 a month before reaching the deductible [4] Group 3: Company Overview - Eli Lilly is a global pharmaceutical leader focused on developing medicines for diabetes, obesity, cancer, and immunological disorders, with notable products including Mounjaro and Zepbound [5]

Core Insights - Eli Lilly has experienced significant growth, particularly due to its weight loss drug portfolio, which includes tirzepatide marketed as Mounjaro and Zepbound [1][2] - The company has seen over 100% stock growth in the past three years, despite a dip in the current year [3] - A potential catalyst for further growth is the upcoming FDA decision on orforglipron, an oral weight loss candidate, expected on April 10 [6][9] Company Overview - Eli Lilly's tirzepatide has generated over $11 billion in revenue, with triple-digit growth reported for both Mounjaro and Zepbound in the latest quarter [5] - The drug is part of the GLP-1 class, aiding in appetite control and blood sugar management [4] - Orforglipron offers a more convenient oral option compared to injectable drugs, which may enhance its market appeal [7][8] Market Position - Eli Lilly holds a 60% share of the U.S. weight loss drug market, positioning it well for future growth as the market is projected to reach nearly $100 billion by the end of the decade [11] - The convenience of orforglipron could lead to higher margins for the company due to easier manufacturing and storage [8] Investment Considerations - Analysts suggest that the current valuation of Lilly stock is more attractive than in previous months, making it a potentially good investment opportunity [9] - Long-term investment in quality stocks like Lilly is emphasized, regardless of short-term fluctuations [12]

证券研究报告 | 2026年03月22日 美股市场速览 弱于大市 资金加速流出，盈利显著上修 价格走势：多数行业回撤，能源与银行较强 本周，标普 500 指数-1.9%（上周-1.6%），纳斯达克综指-2.1%（上周-1.3%）。 风格：大盘价值（罗素 1000 价值-1.3%）＞小盘价值（罗素 2000 价值-1.5%） ＞小盘成长（罗素 2000 成长-1.8%）＞大盘成长（罗素 1000 成长-2.4%）。 3 个行业上涨，21 个行业下跌。上涨的主要有：能源（+2.8%）、银行（+1.7%）、 综合金融（+0.1%）；下跌的主要有：汽车与汽车零部件（-5.4%）、公用事 业（-5.0%）、食品与主要用品零售（-4.7%）、食品饮料与烟草（-4.6%）、 材料（-4.4%）。 资金流向：整体加速流出，少量流入能源 本周，标普 500 成分股估算资金流（涨跌额 x 成交量）为-155.5（亿美元， 下同），上周为-27.1，近 4 周为-313.9，近 13 周为-464.9。 4 个行业资金流入，19 个行业资金流出，1 个基本持平。资金流入的主要有： 能源（+6.6）、银行（+2.1）、运输（+1.4 ...

Eli Lilly’s experimental weight-loss drug retatrutide met the primary and key secondary endpoints in a trial, showing significant reductions in weight loss and blood sugar levels. https://t.co/OFBUzypgGt ...

Core Viewpoint - Eli Lilly has experienced a decline in share price since reaching a $1 trillion market valuation, with concerns about its valuation and potential competition in the weight management market [1] Group 1: Market Position and Competition - Eli Lilly maintains a strong lead in the anti-obesity market, with new product launches expected to solidify its position and expand its market reach [2] - The company is preparing to launch orforglipron, an oral GLP-1 candidate, which could attract new patients who prefer oral therapies over subcutaneous options [2] - Orforglipron has shown strong clinical trial performance, positioning it as a potential best-in-class medicine in diabetes and obesity treatment [3] Group 2: Product Pipeline and Revenue Sources - Eli Lilly is targeting patients with high body mass indexes with retatrutide, which has demonstrated a remarkable 28.7% mean weight loss in a phase 3 study [3][4] - The company has a diverse portfolio beyond weight management, including billion-dollar drugs like Verzenio, which generated $5.7 billion in sales last year, and Taltz, which grew sales by 9% to $3.6 billion [6][7] - Eli Lilly's aggressive expansion into various therapeutic areas, including pain management, oncology, and immunology, supports its revenue growth strategy [7] Group 3: Valuation and Growth Potential - Eli Lilly trades at a forward earnings multiple of 27x, significantly higher than the healthcare sector average of 17.1x, reflecting its faster revenue and earnings growth compared to peers [8] - The company's deep pipeline of candidates is expected to drive growth in the medium term, making the stock attractive despite its premium valuation [8]

Eli Lilly’s experimental drug retatrutide met trial endpoints, showing significant weight loss and blood sugar reductions. https://t.co/t4a97OCbBI ...